Price
No data yet.
Social Signal Score
Analyst Ratings
58 analystsRevenue
$8.30B+13.39%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel O'Day
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 17,000
- Beta
- 0.36
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 3.99
Financials
Revenue
$8.30B+13.4%Net Income
$2.43B-21.8%EBITDA
$4.07B-9.0%Free Cash Flow
$4.80B+44.7%EPS (diluted)
$1.94-17.1%Shares Outstanding (diluted)
1.25B-5.7%Operating Expenses
$3.25BCash & Debt
$6.44BReturn of Capital
$1.41BRevenue by Segment (annual)
$29.44BDividend per Share
$0.82Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $29.44B | $8.51B | $6.84 |
| 2024 | $28.75B | $480.00M | $0.38 |
| 2023 | $27.12B | $5.67B | $4.54 |
| 2022 | $27.28B | $4.59B | $3.66 |
| 2021 | $27.30B | $6.22B | $4.96 |
| 2020 | $24.69B | $123.00M | $0.10 |
| 2019 | $22.45B | $5.39B | $4.24 |
| 2018 | $22.13B | $5.46B | $4.20 |
| 2017 | $26.11B | $4.63B | $3.54 |
| 2016 | $30.39B | $13.50B | $10.08 |
| 2015 | $32.64B | $18.11B | $12.37 |
| 2014 | $24.89B | $12.10B | $7.95 |
| 2013 | $11.20B | $3.08B | $2.01 |
| 2012 | $9.70B | $2.59B | $1.71 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from GILD's reported EPS growth of 11.3% a year over 13 years.
- EPS in 5 years
- $11.68
- Implied price
- $210.31
- Return from $168.98
- 4.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $104.56 — -38.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| 1.3% | -12.3% | -8.3% | -4.9% | -1.9% | 0.7% |
| 6.3% | -8.0% | -3.8% | -0.2% | 2.9% | 5.7% |
| 11.3% | -3.7% | 0.7% | 4.5% | 7.7% | 10.7% |
| 16.3% | 0.7% | 5.3% | 9.2% | 12.6% | 15.6% |
| 21.3% | 5.0% | 9.8% | 13.9% | 17.4% | 20.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
63+25.00%Social Signal Score
Mentions (100)
- News (RSS)fool·8h ago·Neutral
Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here’s Why the Streak Looks Safe. Gilead's consistent cash flows from HIV therapies help sustain its dividend.
View source ↗ - Newsfool.com·13h ago·Neutral
Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe. It's also seeing rising sales from liver disease and oncology products. Gilead recently raised full-year guidance for revenue and EPS.
View source ↗ - Newszacks.com·4d ago·Neutral
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
View source ↗ - News (RSS)seekingalpha·5d ago·Positive
Gilead Sciences, Inc. (GILD) Presents at UBS Global Biopharma Conference 2026 Transcript
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Gilead Sciences, Inc. (GILD) Presents at UBS Global Biopharma Conference 2026 Transcript Gilead Sciences, Inc. (GILD) Presents at UBS Global Biopharma Conference 2026 Transcript
View source ↗ - Newsmarketbeat.com·5d ago·Negative
Gilead Sciences Maps Growth Beyond BIKTARVY With HIV, Cancer and Inflammation Drugs Gilead Sciences NASDAQ: GILD expects HIV and oncology to drive growth through the rest of the decade while it builds an inflammation business for the 2030s, executives said at a London healthcare conference.
View source ↗ - Newsmarketbeat.com·5d ago·Neutral
Gilead Sciences Bets on HIV Prevention Growth Despite $1.5 Billion Biktarvy Headwind Gilead Sciences NASDAQ: GILD expects its expanding HIV prevention portfolio and a potential new cell therapy for multiple myeloma to support growth, even as a negotiated price change for its HIV treatment Biktarvy creates an anticipated $1.5 billion headwind in 2028, Chief Financial Officer Andy Dickinson said at an investor conference.
View source ↗ - News (RSS)seekingalpha·5d ago·Neutral
Gilead: Growth Supports A Hold Despite A Valuation Premium
View source ↗ - News (RSS)seekingalpha·12d ago·Positive
Gilead Sciences, Inc. (GILD) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Gilead Sciences, Inc. (GILD) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript Gilead Sciences, Inc. (GILD) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·12d ago·Neutral
Gilead Sciences Targets 200 Treatment Centers for Potential Anito-Cel Launch Gilead Sciences NASDAQ: GILD is preparing for a potential launch of its multiple myeloma cell therapy anito-cel, with plans to build on the treatment-center relationships and manufacturing capabilities established by its existing CAR-T products, a company executive said.
View source ↗ - Newsfool.com·12d ago·Positive
Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy? The healthcare company's growth rate has been showing significant improvement in recent periods. Its diversified business has been generating positive growth across multiple therapeutic areas.
View source ↗ - News247wallst.com·15d ago·Negative
Gilead Pays a $3.28 Annual Dividend Despite Negative Earnings. Is It Safe? A red ink EPS figure usually spells trouble for retirees counting on a payout. Gilead's loss traces back to one strange quarter, and a single cash metric reveals whether the dividend checks are really at risk.
View source ↗ - PodcastCompound And Friends·16d ago·Negative
term is tech, which is quite interesting, given everything that else is going on. But we love to healthcare story right now. But I would just caution. And I think this is very important for your listeners to understand. The Democrats are going to come in and make healthcare their number one priority. It has been no part of this campaign. But what does that mean? Okay. So what do they want to do with it? Two two tracks. The first track is ambition. The ambition is what do we want to do? Well, nat
View source ↗ - News (RSS)fool·17d ago·Neutral
Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe. Gilead Sciences increased its quarterly dividend by 3.8% this year.
View source ↗ - Newsfool.com·17d ago·Positive
Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe. Gilead's HIV therapies generate strong free cash flow. The company is successfully branching out into oncology and anti-inflammatory therapies.
View source ↗ - Newszacks.com·18d ago·Neutral
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - Newsfool.com·21d ago·Positive
1 Dividend-Paying Biotech Stock to Buy Hand Over Fist in November The company is having a great year.
View source ↗ - News (RSS)marketwatch·23d ago·Neutral
The big winners of the tech wreck are biopharma stocks The shares of large drugmakers like Lilly, Gilead and J&J keep hitting record highs.
View source ↗ - News (RSS)seekingalpha·23d ago·Negative
Gilead: The Business Is Growing, But The Valuation No Longer Works
View source ↗ - Newsseekingalpha.com·23d ago·Negative
Gilead: Q3 Earnings Overview - It's Time To Consider Selling After Stellar Year Gilead Sciences, Inc. delivered its strongest growth in a decade, with Q3 revenues up 16% ex-Veklury and robust HIV franchise performance. GILD's HIV division remains dominant, but Biktarvy faces 2028 Medicare price controls, expected to reduce revenue by $1.5bn that year. Oncology and immunology franchises lag, with mixed M&A results and limited near-term growth outside HIV despite heavy investment.
View source ↗ - News (RSS)zerohedge·23d ago·Neutral
… in June, climbs 4% after posting revenue of $3.3 billion in the four months ending in September, an increase of 9.2% over the same period last year.Gilead Sciences (GILD) rises 4% after the biopharmaceutical company boosted its product sales guidance for the full year.Intel (INTC) plummets 25% after the chipmaker’s outlook was much weaker than expected, due in part to sluggishness in PCs.Mondelez International (MDLZ) is up 7% after the company said it would acquire a majority stake in Undercove…
View source ↗ - Newszacks.com·23d ago·Positive
GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth Gilead tops Q3 earnings and revenue estimates as HIV sales, Trodelvy and Livdelzi drive growth, prompting an increase in 2026 product sales guidance.
View source ↗ - Newszacks.com·23d ago·Positive
GILD Q3 Earnings Call Highlights Raised Outlook and Pricing Risks Gilead Sciences, Inc. GILD raised its 2026 sales outlook following strong third-quarter growth while providing new details on a significant Biktarvy pricing headwind expected in 2028.
View source ↗ - Newsseekingalpha.com·23d ago·Neutral
Gilead: The Business Is Growing, But The Valuation No Longer Works Gilead Sciences faces valuation headwinds despite strong Q3 results and successful HIV, Trodelvy, and Yeztugo growth. Medicare pricing will reduce Biktarvy revenue by $1.5 billion annually starting in 2028, intensifying GILD's dependence on HIV. Q3 HIV growth was inflated by inventory build and a favorable channel mix, making it unsustainable for future quarters.
View source ↗ - Newsseekingalpha.com·23d ago·Neutral
Gilead Sciences: Why I Remain Bullish After Q3 Gilead Sciences had a strong Q3. Sales of Trodelvy, a Trop-2-directed antibody-drug conjugate approved for the treatment of breast cancer, were $506 million, up 41.7% YoY and 10.7% QoQ. On October 22, Gilead agreed to acquire PepStar's oral IL-23R inhibitor program, including HCXT-2001, for $1.275 billion upfront.
View source ↗ - Newsseekingalpha.com·23d ago·Positive
Gilead Sciences, Inc. (GILD) Q3 2026 Earnings Call Transcript Gilead Sciences, Inc. ( GILD ) Q3 2026 Earnings Call October 29, 2026 4:30 PM EDT Company Participants Jacquie Ross - Senior Vice President of Treasury & Investor Relations Daniel O'Day - Chairman & CEO Johanna Mercier - Chief Commercial & Corporate Affairs Officer Dietmar Berger - Chief Medical Officer Andrew Dickinson - Executive VP & CFO Cindy Perettie - Executive Vice President of Kite Conference Call Participants Umer Raffat - Ev…
View source ↗ - News (RSS)investing·24d ago·Neutral
Gilead hikes 2026 sales outlook, says Medicare cuts Biktarvy price by 38% starting in 2028
View source ↗ - News (RSS)investing·24d ago·Neutral
Why is Gilead Sciences stock surging today?
View source ↗ - Newszacks.com·24d ago·Neutral
Gilead (GILD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
View source ↗ - Newsmarketbeat.com·24d ago·Negative
What Gilead Sciences (GILD) Said on Its Q3 Earnings Call Gilead Sciences NASDAQ: GILD reported third-quarter 2026 base business sales growth of 16% year over year, its strongest growth rate in more than a decade, as HIV products, TRODELVY and Livdelzi drove performance. The company also raised its full-year base business revenue outlook while outlining the expected impact of Medicare drug pricing on BIKTARVY beginning in 2028.
View source ↗ - Newszacks.com·24d ago·Positive
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates Gilead Sciences (GILD) came out with quarterly earnings of $2.55 per share, beating the Zacks Consensus Estimate of $2.17 per share. This compares to earnings of $2.47 per share a year ago.
View source ↗ - Newsbenzinga.com·24d ago·Positive
Gilead Sciences Q3 2026 Earnings Call Transcript Gilead Sciences (NASDAQ:GILD) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.
View source ↗ - Newswsj.com·24d ago·Neutral
Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength The biopharmaceutical company said it now expects full-year product sales of $31 billion to $31.3 billion, up from $30.1 billion to $30.4 billion.
View source ↗ - News (RSS)zerohedge·24d ago·Neutral
Tech Futures Tumble As Alphabet Plunges, Small Caps Rise Ahead Of PCE, ECB Tech Futures Tumble As Alphabet Plunges, Small Caps Rise Ahead Of PCE, ECB US futures are lower, with Nasdaq contracts sliding as Alphabet's ugly search miss revived the "is AI capex paying off" debate, while Microsoft's Azure beat and lighter capex, a roughly 1% drop in oil on fresh US-Iran diplomacy chatter and news that Christine Lagarde will quit the ECB nine months early round out the morning's drivers; as a result s
View source ↗ - 4chan /biz/biz·24d ago·Positive
>>62829205 >>62829206 AI pozzed Elon's formerly neg hole. Calls on GILD.
View source ↗ - News247wallst.com·25d ago·Neutral
3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead Eli Lilly's EPS estimate collapsed by a third in just 30 days, Merck faces a comparison it cannot repeat, and Gilead is burning through cash fast.
View source ↗ - Newszacks.com·26d ago·Positive
Gilead to Report Q3 Earnings: How Should You Play the Stock Now? Gilead Sciences heads into Q3 earnings with strong HIV sales, Yeztugo momentum and expanding oncology prospects, but competitive pressures warrant caution.
View source ↗ - Newszacks.com·27d ago·Neutral
Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.
View source ↗ - News (RSS)fool·28d ago·Positive
Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? Both of these biotech stocks could be appealing to income investors.
View source ↗ - News (Marketaux)manilatimes.net·31d ago·Negative
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer BioNTech enters a clinical trial collabo[+328 characters]
View source ↗ - Newsbusinesswire.com·31d ago·Positive
…on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026 FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic hepatitis delta virus (HDV) infection at The Liver Meeting® 2026, hosted by the American Association for the Study of Liver Diseases (AASLD), November 5-9 in Denver, Colorado. The data will examine durability of response, pat…
View source ↗ - Newszacks.com·32d ago·Positive
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note Gilead Sciences (GILD) concluded the recent trading session at $153.57, signifying a -1.88% move from its prior day's close.
View source ↗ - News (Marketaux)gurufocus.com·34d ago·Positive
Gilead Sciences (GILD) Reports Promising Mid-Stage Trial Results for Emvistegrast in Ulcerative Colitis On October 19, 2026, Gilead <em[+351 characters]
View source ↗ - Newszacks.com·34d ago·Positive
All You Need to Know About Gilead (GILD) Rating Upgrade to Buy Gilead (GILD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newsreuters.com·34d ago·Neutral
Gilead's pill succeeds in mid-stage bowel disease trial Gilead's pill succeeds in mid-stage bowel disease trial
View source ↗ - News (RSS)fool·35d ago·Positive
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow? The company's recent momentum continues unabated.
View source ↗ - Newsfool.com·35d ago·Positive
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow? Gilead Sciences' financial results have been strong this year. The company could improve even more thanks to recent approvals and label expansions.
View source ↗ - Newszacks.com·38d ago·Neutral
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts Gilead Sciences (GILD) closed the most recent trading day at $157.48, moving +2.57% from the previous trading session.
View source ↗ - News (RSS)marketwatch·38d ago·Negative
Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs.
View source ↗ - Newszacks.com·38d ago·Neutral
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
View source ↗ - Newszacks.com·44d ago·Neutral
Gilead Sciences (GILD) Laps the Stock Market: Here's Why Gilead Sciences (GILD) closed the most recent trading day at $151.17, moving +2.77% from the previous trading session.
View source ↗ - News (Marketaux)manilatimes.net·46d ago·Positive
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia Nurix is also advancing multiple potenti[+342 characters]
View source ↗ - News (RSS)seekingalpha·47d ago·Positive
Gilead: Buying Growth Isn't Free, And The Discounted Cash Flow Model Knows It
View source ↗ - Newszacks.com·51d ago·Positive
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know Gilead Sciences (GILD) closed the most recent trading day at $144.74, moving 1.87% from the previous trading session.
View source ↗ - Newsbarrons.com·52d ago·Neutral
More Upside Awaits for Gilead Sciences Stock. Stay Invested. Gilead shares are up 35% since Barron's highlighted them, but our catalysts have yet to fully play out.
View source ↗ - Newszacks.com·52d ago·Neutral
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
View source ↗ - Newszacks.com·53d ago·Neutral
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors In the latest trading session, Gilead Sciences (GILD) closed at $149.45, marking a -1.21% move from the previous day.
View source ↗ - News (RSS)seekingalpha·60d ago·Neutral
Gilead: HIV Growth Is Not Enough At The Current Price
View source ↗ - Newsbusinesswire.com·66d ago·Neutral
…l Society, says AHF MEXICO CITY--(BUSINESS WIRE)-- #Gilead--AIDS Healthcare Foundation (AHF), the world's largest HIV care provider, welcomes a new agreement between Gilead Sciences and the Pan American Health Organization (PAHO) that could expand access to lenacapavir for HIV prevention in 14 countries across Latin America. The agreement represents a positive step toward expanding access in the region and a victory for civil society. AHF was among the first organizations to mobilize around conc…
View source ↗ - Newszacks.com·66d ago·Neutral
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
View source ↗ - Newszacks.com·67d ago·Neutral
Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.
View source ↗ - News (RSS)seekingalpha·68d ago·Positive
Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·68d ago·Neutral
Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances Gilead Sciences NASDAQ: GILD executives outlined plans to expand the company's HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief Executive Officer Dan O'Day describing the company as being at an “inflection point in value.”
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·69d ago·Neutral
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.42, denoting a +1.88% move from the preceding trading day.
View source ↗ - News (RSS)yahoo·72d ago·Negative
Gilead Wins Appeals Court Ruling Blocking Imported HIV Drug Sales
View source ↗ - Newsseekingalpha.com·73d ago·Positive
Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·73d ago·Positive
Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth Gilead Sciences NASDAQ: GILD CFO Andy Dickinson told attendees at the Cantor Global Healthcare Conference that the company sees continued growth opportunities across its HIV prevention and treatment businesses, while advancing programs in inflammation, oncology and cell therapy.
View source ↗ - Newsseekingalpha.com·73d ago·Positive
Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·73d ago·Neutral
Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode Gilead Sciences NASDAQ: GILD Chief Medical Officer Dietmar Berger outlined the company's priorities across HIV, oncology and inflammation at the Wells Fargo conference, describing a portfolio that has expanded through internal development and acquisitions and is now entering a period of prioritization and execution.
View source ↗ - Newszacks.com·75d ago·Negative
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.64, denoting a -2.88% move from the preceding trading day.
View source ↗ - News (Marketaux)insidermonkey.com·75d ago·Positive
Bixlenvo Gives Gilead a New HIV Growth Path. How Large is the Market? Gilead Sciences, I[+202 characters]
View source ↗ - News (RSS)fool·78d ago·Neutral
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play? Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.
View source ↗ - Newsfool.com·78d ago·Positive
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play? Gilead is best known for its dominant HIV franchise. But the company has been actively diversifying via acquisitions.
View source ↗ - News247wallst.com·79d ago·Negative
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them? Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a decade out.
View source ↗ - Newszacks.com·82d ago·Neutral
Can Bixlenvo Unlock New Growth for Gilead's HIV Business? GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.
View source ↗ - Newszacks.com·82d ago·Positive
Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock? Gilead (GILD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
View source ↗ - Newszacks.com·82d ago·Neutral
Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest? When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
View source ↗ - Newszacks.com·86d ago·Neutral
Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet option for patients on complex therapies.
View source ↗ - Newsreuters.com·87d ago·Negative
US FDA approves Gilead's once-daily combination pill for HIV treatment The U.S. Food and Drug Administration has approved Gilead Sciences' once daily oral combination pill for treatment of adults whose HIV has already been reduced to very low levels, the company said on Thursday.
View source ↗ - Newscnbc.com·87d ago·Negative
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients The Food and Drug Administration approved a once-daily HIV pill from Gilead that could help simplify care for some patients whose virus is already under control but who remain on complicated treatment regimens. The tablet combines bictegravir, the backbone of Gilead's blockbuster HIV pill Biktarvy, with lenacapavir, a centerpiece of the company's long-term strategy for HIV treatment and prevention.
View source ↗ - Newsbusinesswire.com·87d ago·Negative
… Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the first and only STR option for virologically suppressed people wi…
View source ↗ - Newsfool.com·88d ago·Neutral
Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting Since earnings, investors have focused mainly on the biotech company's growth potential with its HIV PrEP medicines.
View source ↗ - Newszacks.com·89d ago·Neutral
EC Approves Label Expansion of GILD's Trodelvy in First-line Metastatic TNBC Trodelvy's latest EU approval with Keytruda expands its first-line metastatic TNBC use, strengthening Gilead???s oncology growth opportunity.
View source ↗ - Newsbusinesswire.com·90d ago·Neutral
…of Gilead's Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab) for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior sy…
View source ↗ - News (Marketaux)finance.yahoo.com·90d ago·Positive
Gilead’s HIV Business is Surging, but is the Company Too Dependent on One Franchise? Gilead Sciences, I[+282 characters]
View source ↗ - News (RSS)yahoo·91d ago·Negative
Pfizer vs. Gilead: Which Drugmaker Has the Stronger Growth Story?
View source ↗ - Newsdefenseworld.net·92d ago·Negative
Advisors Capital Management LLC Takes Position in Gilead Sciences, Inc. $GILD Advisors Capital Management LLC bought a new position in Gilead Sciences, Inc. (NASDAQ: GILD) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 31,697 shares of the biopharmaceutical company's stock, valued at approximately $4,005,000. Other institutional investors and hedge funds
View source ↗ - News (RSS)seekingalpha·95d ago·Neutral
Gilead rises for the seventh straight session
View source ↗ - Newszacks.com·96d ago·Positive
Is Gilead's Expanding HIV Portfolio a Growth Catalyst? Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.
View source ↗ - Newsfool.com·96d ago·Negative
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited. The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs.
View source ↗ - News (RSS)thestreet·97d ago·Negative
Gilead yanks out a thorn in its side in major court ruling A federal appeals court just handed Gilead Sciences (GILD) a legal win that extends into the company's revenue. The decision blocks a group of companies from importing cheaper foreign versions of Gilead's top HIV drug and selling them to American patients. For a company that relies heavily on a ...
View source ↗ - News (RSS)seekingalpha·98d ago·Positive
Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal
View source ↗ - News (RSS)yahoo·99d ago·Neutral
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?
View source ↗ - Newscnbc.com·100d ago·Positive
Court rules companies can't import Gilead medications from overseas in blow to AFP health programs A U.S. Court of Appeals on Thursday upheld a preliminary injunction against several AFPs and related businesses. The ruling could pave the way for the growing alternative funding programs industry to shrink.
View source ↗ - News (RSS)seekingalpha·103d ago·Neutral
SA analyst upgrades/downgrades: INTC, AMD, ANET, GILD
View source ↗ - News (RSS)investing.com·103d ago·Neutral
Gilead Sciences options activity points to institutional conviction on 2026 upside
View source ↗ - Newsseekingalpha.com·104d ago·Positive
Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade) Gilead's R&D pipeline gained momentum in the first half of 2026, adding several potential growth drivers. Sales of Biktarvy, the flagship of Gilead's HIV franchise, rose 6.9% year-over-year and 12.2% QoQ to ~$3.77 billion in the second quarter. On the other hand, Livdelzi, a PPARδ agonist, generated $167 million in revenue for Gilead, up 114.1% YoY.
View source ↗ - News (RSS)wsj·110d ago·Negative
Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue The biopharmaceutical company lowered its full-year forecast for Veklury after sales of the Covid-19 treatment fell 81% in the second quarter.
View source ↗
Earnings
Tue, Feb 9(in 3 months)
Consensus estimate $1.24 per share
Typical surprise +6.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 29$2.55 vs $2.19beat
- Tue, Aug 4$-6.75 vs $-7.25beat
- Thu, May 7$2.03 vs $1.91beat
- Tue, Feb 10$1.86 vs $1.81beat
- Thu, Oct 30$2.47 vs $2.13beat
- Thu, Aug 7$2.01 vs $1.96beat
Estimates and results for GILD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GILD officers and directors.
- Bought
- —
- Sold
- $51.9m
0 trades
51 trades
- Mercier Johannasold
- Mercier Johannasold
- Mercier Johannasold
- Dickinson Andrew Dsold
- Kramer Kelly A.sold
- Kramer Kelly A.sold
- Kramer Kelly A.sold
- Kramer Kelly A.sold
49 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Sep 7, 2026 (28d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 12, 2026 (36d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 5, 2026 (817d later)Buy$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 5, 2026 (817d later)Buy$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 5, 2026 (817d later)Buy$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Jared Moskowitzhouse · FL23 · disclosed Jun 22, 2026 (47d later)Buy$1,001 - $15,000
- Jared Moskowitzhouse · FL23 · disclosed Jun 22, 2026 (47d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Feb 27, 2026 (31d later)Buy$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Oct 10, 2025 (17d later)Sell$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Sep 12, 2025 (318d later)Buy$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (42d later)Sell$15,001 - $50,000
- Marjorie Taylor Greenehouse · GA14 · disclosed Jun 19, 2025 (13d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jun 12, 2025 (29d later)Sell$1,001 - $15,000
- John Boozmansenate · AR · disclosed May 14, 2025 (28d later)Sell$1,001 - $15,000
- Marjorie Taylor Greenehouse · GA14 · disclosed May 7, 2025 (2d later)Buy$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Apr 14, 2025 (14d later)Buy$15,001 - $50,000
- Josh Gottheimerhouse · NJ05 · disclosed Apr 11, 2025 (35d later)Buy$1,001 - $15,000
- Carol Devine Millerhouse · WV01 · disclosed Apr 11, 2025 (32d later)Buy$1,001 - $15,000
- Marjorie Taylor Greenehouse · GA14 · disclosed Dec 30, 2024 (6d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
